The post Tế bào Purkinje, những tế bào thần kinh lớn trong tiểu não, nằm ở phía sau và phía dưới của não. appeared first on First, Do No Harm!.

1979 Titer plane technique (immunofluorescence substrates are dipped into samples and reagents from above)

1983 BIOCHIPs for tissue sections, antigen dots, blot strips and nucleotide arrays, BIOCHIP mosaics

1983 Chemical coupling of tissue sections to microscope slides

1987 to date: Numerous preparation processes for tissue, cells and proteins for the diagnosis of antibodies. Areas of autoimmunity, infectiology, allergy

1990 Description Autoantibodies against gray matter in diabetes mellitus

1995 EUROBLOT technology (slides with antigen-printed blot strips)

1996 Discovery of autoantibodies against lipocytes in lipoatrophy

1996 EUROPLUS technology: combination of tissue sections with antigen spots

1999 Autoantibodies against the tunica choroidea in chronic recurrent chorioretinitis

2003 World’s first serological SARS diagnostic

2004 Autoantibodies against nucleosomes are specific to lupus erythematosus

2005 Full automation of BIOCHIP production

2006 LED illumination for fluorescence microscope

2007 Recombinant designer antigen BP 180 for the diagnosis of bullous pemphigoid

2007 EUROLabOffice (organization software for the serological diagnostic laboratory)

2007 Gliadin peptide analog designer antigen for serological diagnosis of celiac disease

2008 EUROTide (convection in the miniaturized reaction approach)

2009 Nucleosome-mediated coupling of nDNA to ELISA surfaces

2009 EUROPattern (fully automatic microscope & evaluation software cell nucleus antibodies)

2009 DNA-bound lactoferrin is a target antigen in ulcerative colitis

2009 CUZD1 and GP2 are the (long-sought) autoantigens in Crohn’s disease

2010 BIOCHIP mosaics from recombinant cell substrates for autoimmune diagnostics in gastroenterology, neurologyand dermatology

2010 IgA and IgM anti-glutamate receptor antibodies (NMDA) in psychosis and dementia

2010 Identification of autoantibodies against aquaporin-4 via complement

2011 Fully automated virtual fragmentation of tissue sections

2012 Ten-channel pipetting robot

2013 Pathohistochemistry Incubation Forum

2013 Recombinant vaccine (OspC) for Lyme disease prophylaxis, trial in mice

2014 MERGITE! Fully automatic bidet-like washing of separate slide fields in immunohistochemical incubations as part of antibody diagnostics

2015 Portioned reagents in capillaries (including for Accentis, 2021)

2017 Detection of antibodies in a tissue section by co-incubation with a detector substrate

2020 World’s first, safest and successful anti-Covid-19 vaccination (March 26, 2020), with a harmless synthetic antigen that resembles the receptor-binding domain of the Covid-19 pathogen

2021 Global market launch of the fully automatic Accentis: random access luminescence analysis using collated capillaries with portioned antigen-coated beads

2022 Identification of several autoantibody target structures from the field of neurology and dermatology in the last fifteen years

2022 Antibodies against Zinc finger and SCAN domain containing proteins in neurological diseases by PhiP-Seq (phage immunoprecipitation sequencing) using tens of thousands of artificial gene sequences

Prof. Dr. med. Winfried Stöcker

The post <strong>MILESTONES: CONTRIBUTIONS TO MEDICAL RESEARCH AND DEVELOPMENT IN WHICH THE UNDERSIGNED WAS SIGNIFICANTLY INVOLVED</strong> appeared first on First, Do No Harm!.

The post The Help appeared first on First, Do No Harm!.

The post XBB,BA,CH,BQ… appeared first on First, Do No Harm!.

Journal of Vaccines, Immunology and Immunopathology

Stöcker W. J Vaccines Immunol 7: 173. www.doi.org/10.29011/2575-789X.000173

www.gavinpublishers.com

Short Commentry

LubecaVax: The Safe way out of the

Anti-Corona Vaccination Chaos

Winfried Stöcker*

Clinical-Immunological laboratory, Am Sonnenberg 9, D-23627 Groß Grönau, Germany

*Corresponding author: Winfried Stöcker, Clinical-Immunological laboratory, Am Sonnenberg 9, D-23627 Groß Grönau, Germany

Citation: Stöcker W (2022) LubecaVax: The Safe way out of the Anti-Corona Vaccination Chaos. J Vaccines Immunol 7: 173. DOI:

10.29011/2575-789X.000173

Received Date: 03 June, 2022; Accepted Date: 28 June, 2022; Published Date: 01 July, 2022

In recent months, a large number of dangerous side effects of RNA- and virus-based (genetic) vaccinations have been observed. In contrast, immunization with the protein-based LubecaVax is almost free of side effects, and it results in high levels of neutralizing antibodies against corona viruses in 97% of vaccinated individuals. Due to its well-proven concept over many decades, this vaccination does not pose the innate risks which genetic vaccines reveal more and more. In the meantime, experience with the protein-based LubecaVax has been gained with about 60,000 vaccinations. They were started in March 2020, based on the Receptor-Binding Domain (RBD) of the corona virus. Initially RBD of wild-type was used, since August 2021 RBD of the Delta virus, and since February 2022 RBD of Omicron plus wild-type. The vaccines do not contain any foreign genetic material – neither RNA nor the DNA of weakened viruses, and are by far better accepted by the public, since many people regard vaccinations with gene-ferries dangerous. LubecaVax hardly triggers allergic reactions, is low- priced and easy to be produced and to handle. Any physician can prepare it in his practice and administer it legally on an individual basis at the request of his patients. The components of the vaccine do not need to be transported deep-frozen and can be stored in the refrigerator (the few well-meant donations of provisionally approved vaccines in many cases fail due to logistics and the requirement of a cold chain).

The German Paul Ehrlich Institute either did not realize the potential of the Lübeck vaccine or eagerly wanted to leverage a new vaccination principle, which many scientists consider dangerous, and therefore blocked the way for an approval of the Lübeck vaccination. Having used the Lübeck anti-corona virus vaccine developed in March 2020 in the correct manner, the whole of Germany would presumably be free of the corona virus epidemic by now – if self-important authorities would not have

prohibited the development and application of this vaccination.

In the warm season, in Germany the risk of infection with corona viruses is again very low. Also, the official vaccinations that have already been given (even though they are dangerous), may have contributed to herd immunity. But it is foreseeable that by the upcoming fall, the pandemic will have us firmly in its grip again. Vaccinated people should not be deceived into a false sense of security: Serum antibody levels for corona virus have been found to drop very rapidly, often to half or less within six months, so that people can soon become infected again after complete basic immunization (as we have experienced with the Delta- virus). However, even high levels do not protect against infection with more mutated variants (example Omicron), but the disease is usually very mild after immunization against wild type and Delta.

For the moment, it is therefore highly recommended to boost twice a year, in any case with an up-to-date recombinant antigen construct. A six-month break can be taken if the antibody concentration in the blood is sufficiently high, but this must be measured. Since RNA- and vector virus-based vaccinations can cause more and more damage with each further booster, only non-dangerous recombinant corona- RBD antigens should be used in the future, such as LubecaVax.

And here is my recommendation to the authorities in Germany: Let physicians exercise their right to treat their patients individually, if that is the patients’ intense desire. Stop depriving them of their basic constitutional right to produce and administer a vaccine in line with the freedom of choice of treatment. If the expectations come true that we will again have to immunize extensively against COVID-19 next fall, 10 million people will want to get a vaccine as LubecaVax. And they will not have to be forced by authorities to do so – what an opportunity! They

Citation: Stöcker W (2022) LubecaVax: The Safe way out of the Anti-Corona Vaccination Chaos. J Vaccines Immunol 7: 173. DOI: 10.29011/2575-789X.000173

are justly afraid of the state-ordered mass experiment with genetic vaccinations! They don’t want to be patronized and they don’t want a uniform press – we had that behind us long ago.

And another piece of advice to all the health authorities in our world: Don’t wait again several months before vaccinating when a new dangerous pathogen is spreading. As was shown with COVID-19, the genetic code of the virus and the epitopes suitable for vaccination were decoded within a few weeks of its first appearance. Let an institution have cell cultures on standby

that can be used to produce harmless protein based vaccines (as in LubecaVax) in large quantities on short notice! The institution must already possess all approvals for such production.

Further information can be found in the articles

“LubecaVax: The individual anti-corona vaccination from Lübeck”, version May 9, 2022 and “Gene-based anti-corona vaccines are dangerous! The pseudo-COVID syndrome”, version May 3, 2022.

The post <strong>Lubecavax: The Safe Way Out Of The</strong> <strong>Anti-Corona Vaccination Chaos</strong> appeared first on First, Do No Harm!.

(Hanoi + Ho Chi Minh City/Vietnam)

You will support online discussion forums, our Q&A lifecycle process, new content production, help subject matter experts prepare for and communicate with customers, work as the administrator on customer-facing webinars, and execute against our community engagement strategy. More than meeting the needs of our agents as stakeholders, we want someone whose personal mission is to make every stakeholder fall in love with being a member of our user community.

Responsibilities:.

• Master all administrative duties and logistical responsibilities it takes to meet our community objectives.It takes a lot of elbow grease to meet our community objectives. Some data and spreadsheets need to be maintained; there are meetings to schedule, stuff that needs to be purchased; and vendors to contact. In short, there’s stuff to do that furthers our mission. We want someone willing to get their hands dirty and is excited to do the needful.
• Work diligently to improve the user community experience for members every day.We want someone who loves what they do and has an unmatched desire for making our stakeholder experience better than it was yesterday, every day. We are looking for someone interested in taking things to the next level, focusing on places we can improve, and measuring themselves based on how delighted our stakeholders are with their user community experience.
• Help stakeholders understand how to participate.In our user community, we want user generated content, our very own YouTube feel, SMEs writing blogs, and answers and information coming to community members from anyone, anywhere. But, many of our stakeholders don’t know how to use our tools to successfully generate content. We need someone committed to talking about how to use our tools to promote the right kinds of user community behavior to anyone that will listen!
• Help people find the content and information they need.One of the biggest challenges to engagement and participation is simply finding what you’re looking for. We want someone who goes out of their way to make finding valuable content as easy as possible for our stakeholders.
• Ensure customer and other stakeholder queries are adequately addressed in a timely fashion.We expect a flood of questions from stakeholders that need routing to the appropriate SME for answers. We also expect SMEs to be busy and need follow-up or encouragement. We expect these same challenges on discussion boards and other areas in our online platform. We want someone who isn’t afraid to hound SMEs to ensure the user community needs are met BUT can also think outside the box and get creative when there are barriers to timely responses.
• Work with subject matter experts and other stakeholders to ensure the creation of value-add content regularly.Content varies in medium and type. You will have to support SMEs in deciding what kind of content to develop and what medium to use. You will also be responsible for engaging the correct SMEs and driving content pieces to closure, including things like ghostwriting or collaboration sessions where you help the SME understand what content should be delivered.
• Dig into the company to help mine out the best topics and sources of information.Sometimes stakeholders will be asking for content to be developed. Other times, you will learn of a new initiative or find a golden nugget of information that you know in your heart will be awesome to share with the user community. You will work as a constant advocate for information that should be hosted on our online platform.
• Measure community engagement and help think up ways to improve engagement.We aren’t just looking for high quantities of members to join our community. We are looking for high-quality interactions and participation. It will be your responsibility to measure and report if what we are doing meets our objectives, delights our stakeholders, and positively impacts our KPIs.
• Partner with Training and Documentation to coordinate the best holistic experience for stakeholders.There are lots of teams developing content for the community to interact with. Some of the most critical relationships for this role is partnering with our Training team and our Documentation team to integrate the resources and deliverables they create into the community experience. We don’t want community members to feel like they are interacting with our Community team versus our Training team or Documentation Team. We want them to feel like they are interacting with Sagitec.
• Of course, there will be a few other duties that we aren’t predicting.As our user community membership and platform grow and evolve, we anticipate that your role will grow and mature in support. That said, the objectives remain the same – curate high-quality content that meets the needs of our stakeholders when they need it.

Qualifications:

• Passionate and excited after reading our job description.
• Great communication skills in English ( and German if possible) and high emotional intelligence.
• Isn’t afraid of ambiguity.
• Dig in and do the work without a lot of handholding.
• Can work with lots of different stakeholders.
• Listen to and identify the needs of many.
• Have an interest in making online communities work, including fostering engagement.

Preferred Qualifications:

• Previously worked for a company with B2B customers, preferable in Health Sciences .
• Experience working on other user communities.
• Experience with Higher Logic.

Education:

• Educational or work background in communications, education/training, marketing or/and Biotech, Biology or Health Sciences.

Compensation and Benefits:

• Full Time/permanent
• plan with company match
• Health insurance
• Flexible spending account
• Paid time off
• Company holidays
• Floating holidays
• Employee assistance program abroad
• Referral program

PLEASE CONTACT OR SEND YOUR CV to  LUBECA HEALTH

The post <strong>B2B Care Manager </strong> appeared first on First, Do No Harm!.